Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RN5681 in Healthy Volunteers
NCT07347678Phase 1Recruiting
- Sponsor
- Ikaria
- Start
- Mar 2026
- Primary completion
- Feb 2027
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 1, randomised trial in hypercholesterolemia comparing RN5681 with Placebo (2 arms). Primary endpoints: Safety and tolerability of subcutaneously administered RN5681 at Day 180 and Metabolic markers of efficacy at Day 180. Started Mar 2026; status: recruiting.
02
Drugs
RN5681
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT07347678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07347678.